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Disclosures
 I have nothing to disclose concerning possible financial or 
personal relationships with commercial entities that may 




Review select oral oncolytic approvals 
in 2019
Discuss the challenges associated 
with oral oncolytics
Identify possible solutions to 




 Historically, chemotherapy has been administered by 
intravenous infusion in an oncology inpatient unit, clinic or 
a physician’s office
 First oral oncolytics approved in 1953
 Mercaptopurine
 Methotrexate
 1953-2014: 29 agents approved in 61 years, averaging 
~2 agents per year
 2019: 7 agents approved in 1 year
 It is estimated that 25%-30% in the research pipeline 
are oral
Weingart SN et al. 2008;6 Suppl 3:S1-14.
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Advantages
Increased control and 
convenience 
Potential increase in the quality 
of life
Potential reduction in travel costs 
and use of healthcare resources
Sustained medication exposure
Disadvantages
Lack of coordinated care
Increased errors
Nonadherence
Limited and difficulty monitoring
Weingart SN et al. 2008;6 Suppl 3:S1-14.
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Oral Oncolytic Approvals in 
2019
 Cabozantinib: Hepatocellular carcinoma, January 14, 2019
 Trifluridine-tipiracil: Gastric or gastroesophageal junction 
(GEJ) adenocarcinoma, February 22, 2019
 Alpelisib: Breast cancer, May 24, 2019
 Erdafitinib: Urothelial carcinoma, April 12, 2019
 Darolutamide: Prostate cancer, July 30, 2019
 Apalutamide: Prostate cancer, September 17, 2019
 Lenvatinib: Endometrial carcinoma, September 17, 2019
 Niraparib: Ovarian, fallopian tube, or primary peritoneal 
cancer, October 23, 2019
 Enzalutamide: Prostate cancer, December 16, 2019
7
Cabozantinib (Cabometyx®)
 Indication: Patients with hepatocellular carcinoma after 
prior therapy with sorafenib
Cabozantinib [package insert]. Alameda, CA: Elexisis; 2019 
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Cabozantinib (Cabometyx®)
Dose Strengths Drug-Drug Interactions Adverse Effects







• Strong CYP3A4 








• Perforations and 
fistulas
• Thrombotic events







• Osteonecrosis of the 
jaw 
• Wound complications
• Reversible posterior 
leukoencephalopathy 
syndrome




• Cabometyx tablets ≠ cabozantinib capsules
• Do not give with food
• ≥1 hour before or ≥2 hours after eating
• Take missed dose if <12 hours to next dose
• Hold ≥28 days prior to surgery 
• Diarrhea (any grade: 63%, Grade 3: 11%): 
• Intolerable Grade 2, Grade 3, or Grade 4: Hold until Grade 1; resume 
at ↓ dose 
• PPE (any grade: 44%, grade 3: 13%): 
• Intolerable Grade 2 or Grade 3: Hold until Grade 1; resume at ↓ dose
• Prophylaxis: Moisturizing creams containing keratolytics 
• Treatment: Urea, clobetasol, pain control
• Hypertension and hypertensive crisis (any grade: 36%, Grade 3:17%): 
• Uncontrolled hypertension: Hold; resume at ↓ dose once controlled
• Severe hypertension not medically manageable or hypertensive crisis: 
Discontinue 
Cabozantinib [package insert]. Alameda, CA: Elexisis; 2019 
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Trifluridine-Tipiracil (Lonsurf®)
 Indication: Patients with metastatic gastric or GEJ 
adenocarcinoma previously treated with ≥2 prior lines of 
chemotherapy that included a fluoropyrimidine, a platinum, 
either a taxane or irinotecan, and if appropriate, HER2/neu-
targeted therapy
Trifluridine-Tipiracil [package insert]. Princeton, NJ: Taiho; 2019 
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Trifluridine-Tipiracil (Lonsurf®)
Dose Strengths Drug-Drug Interactions Adverse Effects
• 35 mg/m2/dose 
orally twice 
daily with food 
on 
• Days 1-5 
• Days 8-12 
• Every 28 
days
• Dosing based 
on trifluridine
• Round nearest 
5 mg
• Maximum: 80 
mg























• If stored outside of original bottle, discard after 30 days
• Dosing schedule: 
• Monday to Friday
• 2 weeks on, 2 weeks off
• Complete blood cell (CBC) prior to and on Day 15 each cycle
• Hold for any of the following:
• Absolute neutrophil count (ANC) <500/mm3 or febrile neutropenia
• Platelets <50,000/mm3
• Grade 3 or 4 non-hematologic adverse effects
• Recover then ↓ dose by 5 mg/m2/dose
• Maximum of 3 dose reductions
• Do not ↑ dose after reduction
• 20 mg/m2 po BID not tolerable: Permanently discontinue
Trifluridine-Tipiracil [package insert]. Princeton, NJ: Taiho; 2019 
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Trifluridine-Tipiracil (Lonsurf®)
Tips & Tools. LONSURF® (trifluridine and tipiracil) tablets. https://www.lonsurf.com/patient-resources/tools.
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Alpelisib (Piqray®)
 In combination with fulvestrant for postmenopausal 
women, and men, with hormone receptor (HR)-positive, 
human epidermal growth factor receptor 2 (HER2)-
negative, PIK3CA-mutated, advanced or metastatic breast 
cancer
Alpelisib [package insert]. East Hanover, NJ: Novartis; 2019 
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Alpelisib (Piqray®)
Dose Strengths Drug-Drug Interactions Adverse Effects
• 300 mg (two 
150 mg film-
coated tablets) 



























Alpelisib [package insert]. East Hanover, NJ: Novartis; 2019 
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Alpelisib (Piqray®)
Dose Level Dose1 Number and Strength of Tablets
Starting dose 300 mg once daily Two 150 mg tablets
First-dose reduction 250 mg once daily One 200 mg tablet and one 50 mg 
tablet
Second-dose reduction 200 mg once daily One 200 mg tablet
1Only one dose reduction is permitted for pancreatitis
2If further dose reduction below 200 mg once daily is required
Severity of Diarrhea Recommendations
Grade 1 (increase of <4 
stools per day over 
baseline)
• Initiate medical therapy and monitor
Grade 2 (increase of 4-6 
stools per day over 
baseline )
• Initiate or intensify medical therapy and monitor
• Hold until Grade ≤1: Resume at same dose level
Grade 3 (increase of ≥7 
stools per day over 
baseline) and Grade 4 
(life-threatening 
consequences)
• Initiate or intensify appropriate medical therapy and 
monitor as clinically indicated. Interrupt dose until 
recovery to Grade ≤1, then resume at the next lower 
dose level





Grade 1 (FPG 
>ULN-160 
mg/dL)
• Initiate or intensify anti-diabetic treatment 
• SOLAR-1 trial: 
• Metformin 500 mg po daily  500 mg po twice daily  500 
mg po with breakfast and 1000 mg po with dinner  1000 
mg po twice daily 
Grade 2 (FPG 
>160-250 
mg/dL) 
• Follow Grade 1 recommendations
Grade 3 (>250-
500 mg/dL) 
• Follow Grade 1 recommendations and consider additional anti-
diabetic medications X1-2 days until improvement
• FPG ↓ to ≤160 mg/dL within 3 to 5 days: Resume at 1 lower dose 
level 
• Not within 3-5 days: Consult physician 
• Not within 21 days: Permanently discontinue
Grade 4 (>500 
mg/dL)
• Follow Grade 1 recommendations, re-check FPG within 24 hours 
and as clinically indicated 
• FPG ↓ to ≤500 mg/dL: Follow Grade 3 recommendations 
• FPG >500 mg/dL: Permanently discontinue
Alpelisib [package insert]. East Hanover, NJ: Novartis; 2019 
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Alpelisib (Piqray®)
Severity of Rash Recommendations
Grade 1 
(<10% body surface area (BSA) with 
active skin toxicity)
• Topical corticosteroid treatment
• Consider + oral antihistamine
Grade 2 
(10-30% BSA with active skin 
toxicity) 
• Initiate or intensify topical corticosteroid + 
oral antihistamine 
• Consider + low dose systemic corticosteroid
Grade 3 (e.g., severe rash not 
responsive to medical management) 
(>30% BSA with active skin toxicity) 
• Initiate or intensify topical/systemic 
corticosteroid + oral antihistamine 
treatment
• Once ≤Grade 1: 
• 1st occurrence: Resume at the same 
dose level 2nd occurrence: Resume at 
next lower dose level 
Grade 4 (e.g., severe bullous, 
blistering or exfoliating skin 
conditions) 
(any % BSA associated with 
extensive superinfection, with IV 
antibiotics indicated; life-threatening 
consequences) 
• Permanently discontinue




• Take with food
• Missed dose: Take up to 9 hours after usual time
• Hyperglycemia (any grade: 6%, Grade 3: 33%)
• Monitor blood glucose and/or FPG 
• First 2 weeks: At least weekly 
• Thereafter: At least 1X every 4 weeks, and as clinically indicated
• Hyperglycemia occurs: As clinically indicated, and ≥ 2X weekly 
until normal
• During anti-diabetic therapy: At least weekly X 8 weeks 
biweekly and as clinically indicated
• Monitor HbA1c every 3 months and as clinically indicated 
• Diarrhea: (any grade: 58%, Grade 3: 7%)
• Pneumonitis: Signs and symptoms 
Alpelisib [package insert]. East Hanover, NJ: Novartis; 2019 
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Erdafitinib (Balversa®)
 Patients with locally advanced or metastatic urothelial 
carcinoma with susceptible fibroblast growth factor receptor 
3 (FGFR3) or FGFR2 genetic alterations, when the disease 
has progressed during or following platinum-containing 
chemotherapy, including within 12 months of neoadjuvant
or adjuvant platinum-containing chemotherapy
Erdafitinib  [package insert]. Northbrook, IL: Astellas; 2019 
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Erdafitinib (Balversa®)
Dose Strengths Drug-Drug Interactions Adverse Effects
• 8 mg (two 4 
mg tablets) po
daily
• ↑to 9 mg (three 
3 mg tablets) 









Avoid, if not possible, 
monitor adverse 
reactions and consider 
dose modifications:
• Strong CYP2C9 or 
CYP3A4 inhibitors 
and inducers
• Moderate CYP2C9 
or CYP3A4 inducers
























9 mg ➝ (three 
3 mg
tablets)


























Phosphate Levels Dose Adjustment Recommendations
5.6-6.9 mg/dL None • Continue
7.0-9.0 mg/dL Hold
• Hold until ↓ <5.5 mg/dL (or baseline)
• Restart at same dose level
• Hyperphosphatemia lasting >1 week: Consider
dose reduction 
>9.0 mg/dL Hold • Hold until ↓ <5.5 mg/dL (or baseline)• Restart at 1 dose level lower
>10.0 mg/dL or significant 
alteration in baseline renal 
function or Grade 3 
hypercalcemia
Hold
• Hold until ↓ <5.5 mg/dL (or baseline)
• Restart 2 dose levels lower
Erdafitinib  [package insert]. Northbrook, IL: Astellas; 2019 
23
Erdafitinib (Balversa®)





Grade 1: Asymptomatic; clinical
or diagnostic observations only
• Hold until resolution
• Within 4 weeks: Resume at 1 lower dose 
level 
• Then, if no recurrence X 1 month: Consider 
re-escalation 
• Not resolved but stable X2 consecutive eye 
exams: Resume at 1 lower dose level
Grade 2: Visual acuity 20/40 or
better or ≤3 lines of decreased 
vision from baseline
• Hold until resolution
• Resolves within 4 weeks: May resume at the 
next lower dose level
Grade 3: Visual acuity worse
than 20/40 or >3 lines of
decreased vision from baseline
• Hold until resolution
• Within 4 weeks: Resume 2 dose levels 
lower
• Recurs: Consider permanent discontinuation
Grade 4: Visual acuity 20/200
or worse in affected eye
• Permanently discontinue




• Missed dose: Take as soon as possible. No double doses
• Hyperphosphatemia (any grade: 76%):
• Levels 14-21 days after initiation
• Monitor levels monthly 
• Restrict phosphate intake to 600-800 mg daily
• >7.0 mg/dL: Consider adding oral phosphate binder until ↓ <5.5 
mg/dL
• Ocular disorders (any grade: 25%, Grade 3: 3%)
• All patients should receive ocular demulcents as needed
• Eye exams
• During first 4 months: Monthly
• Thereafter: Every 3 months
Erdafitinib  [package insert]. Northbrook, IL: Astellas; 2019 
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Lenvatinib (Lenvima®)
 In combination with pembrolizumab, for patients with 
advanced endometrial carcinoma that is not microsatellite 
instability-high (MSI-H) or mismatch repair deficient 
(dMMR), who have disease progression following prior 
systemic therapy and are not candidates for curative 
surgery or radiation
Lenvatinib  [package insert]. Woodcliff Lake, NJ: Eisai; 2019 
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Lenvatinib (Lenvima®)
Dose Strengths Drug-Drug Interactions Adverse Effects













• Drugs that 





• QT interval 
prolongation 
• Hypocalcemia







• Wound healing 
complication 
Lenvatinib  [package insert]. Woodcliff Lake, NJ: Eisai; 2019 
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Lenvatinib (Lenvima®)
Adverse Reaction Severity Recommendations
Hypertension
Grade 3
• Persists despite optimal antihypertensive 
therapy: Hold 
• ≤Grade 2: Resume at reduced dose
Grade 4 • Permanently discontinue
Cardiac Dysfunction 
Grade 3
• Hold until ↓to Grade 0 to 1 or baseline
• Depending on severity/persistence: Resume 
at a reduced dose or discontinue
Grade 4 • Permanently discontinue
Arterial thromboembolic event Any • Permanently discontinue
Hepatotoxicity Grade 3 or 4
• Hold until ↓to Grade 0 to 1 or baseline
• Depending on severity and persistence: 
Either resume at a reduced dose or 
discontinue
• Hepatic failure: Permanently discontinue
Renal failure or impairment Grade 3 or 4
• Hold until ↓to Grade 0 to 1 or baseline
• Depending on severity and persistence: 
Resume at a reduced dose or discontinue





Proteinuria ≥2 g proteinuria in 24 hours 
• Hold until ≤2 g/24 hours
• Resume at a reduced dose





Fistula formation Grade 3 or 4 • Permanently discontinue






• Hold until resolved
• Depending on severity and 
persistence: Resume at a reduced 
dose or discontinue
Other 
Persistent or intolerable Grade 2 or 
3 adverse reaction 
Grade 4 laboratory abnormality 
• Hold until ↓to Grade 0 to 1 or baseline
• Resume at reduced dose
Grade 4 adverse reaction • Permanently discontinue




• Missed dose: Next dose is due within 12 hours, skip the missed dose 
• If cannot swallow capsules, can take with medicine cup and liquid
• Hypertension: Monitor after 1 week  every 2 weeks X first 2 months, 
≥ monthly
• Proteinuria: Monitor prior to and periodically during treatment. 
• ≥2+: Obtain 24-hour urine protein  
• Diarrhea: Take loperamide 4 mg po, then 2 mg every 4 hours or after each 
loose stool 
• QT interval prolongation: 
• Monitor and correct electrolyte abnormalities 
• Monitor electrocardiograms in patients with cardiac conditions or on 
agents that prolong the QT interval
• Impairment of thyroid stimulating hormone suppression/thyroid 
dysfunction: Monitor prior to and monthly during treatment 
• Treat hypothyroidism accordingly
• Wound healing complication: Hold for ≥6 days prior to surgery  
Lenvatinib  [package insert]. Woodcliff Lake, NJ: Eisai; 2019 
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Niraparib (Zejula®)
 Patients with advanced ovarian, fallopian tube, or primary 
peritoneal cancer treated with three or more prior 
chemotherapy regimens and whose cancer is associated 
with homologous recombination deficiency (HRD)-positive 
status





Dose Strengths Drug-Drug Interactions Adverse Effects


















Niraparib  [package insert]. Waltham, MA: Tesaro; 2019 
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Niraparib (Zejula®)
Dose Modifications for Adverse Reactions
Dose Level Dose
Starting dose 300 mg/day (three 100 mg capsules)
First dose reduction 200 mg/day (two 100 mg capsules)
Second dose reduction 100 mg/day* (one 100 mg capsule)
Dose Modifications for Non-Hematologic Adverse Reactions
Non-hematologic CTCAE* ≥ Grade 3 adverse 
reaction where prophylaxis is not considered 
feasible or adverse reaction persists despite 
treatment
• Hold ≤ 28 days or until 
resolution
• Resume at a reduced dose
• ≤2 dose reductions
CTCAE ≥ Grade 3 treatment-related adverse 
reaction lasting more than 28 days while 
patient is administered niraparib 100 
mg/day
• Discontinue medication 
*If further dose reduction below 100 mg/day is required, discontinue 
Niraparib  [package insert]. Waltham, MA: Tesaro; 2019 
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Niraparib (Zejula®)




• Hold ≤28 days and monitor blood counts weekly until platelet counts 
↑≥100,000/μL
• Resume at same or reduced dose 
• If platelet count is <75,000/μL, resume at a reduced dose
Second occurrence:
• Hold ≤28 days and monitor blood counts weekly until platelet counts 
↑≥100,000/μL
• Resume at a reduced dose 






• Hold ≤28 days and monitor blood counts weekly until neutrophil counts 
↑≥1,500/μL or hemoglobin ↑≥9 g/dL
• Resume at a reduced dose 







• Platelet count ≤10,000/μL: Consider transfusion
• Other risk factors such as co-administration of anticoagulation or 
antiplatelet drugs: Consider interrupting these drugs and/or transfusion at 
a higher platelet count
• Resume at a reduced dose
*If myelodysplastic syndrome or acute myeloid leukemia (MDS/AML) is confirmed, discontinue 




• Nausea: Bedtime administration
• Myelodysplastic syndrome/acute myeloid leukemia: Developed <2 months 
to >4 years of therapy
• Bone marrow suppression: 
• Do not start until ≤ Grade 1 hematological toxicity 
• Complete blood count 
• First month: Weekly 
• Next 11 months: Monthly and periodically 
• Hematological toxicities do not resolve ≤28 days following 
interruption: Discontinue and refer to hematologist 
• Cardiovascular effects: Monitor blood pressure and heart rate 
• First 2 months: At least weekly 
• First year: Monthly and periodically
Niraparib  [package insert]. Waltham, MA: Tesaro; 2019 
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Androgen Receptor Inhibitors: 
Enzalutamide (Xtandi®) and 
Apalutamide (Erleada®)
 Patients with metastatic castration-sensitive prostate 
cancer
Darolutamide [package insert]. Whippany, NJ: Bayer; 2019
Apalutamide [package insert]. Guarbo, PR: Janssen Ortho LLC; 2019 
Enzalutamide [package insert]. Northbrook, IL: Astellas; 2019 
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Darolutamide (Nubeqa®)
 Patients with non-metastatic castration-resistant prostate 
cancer 
Darolutamide [package insert]. Whippany, NJ: Bayer; 2019
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Androgen Receptor Inhibitors
Dose Strengths Drug-Drug Interactions
Darolutamide




• 300 mg • Combined P-gp and strong or 
moderate CYP3A4 inducers: Avoid 
• Combined P-gp and strong CYP3A4 
inhibitors: Monitor more frequently 
for adverse reactions
• BCRP substrates: Avoid, if not, 
monitor for adverse reactions and 
consider ↓ BCRP substrate drug 
dose
Apalutamide




• 60 mg • Concomitant use with sensitive 
substrates of CYP3A4, CYP2C19, 
CYP2C9, UGT, P-gp, BCRP, or 
OATP1B1: Avoid
Enzalutamide




• 40 mg • CYP2C8 inhibitors and CYP3A4 
inducers: Avoid, if not, ↓to 80 mg 
po daily 
• CYP3A4 inducers: Avoid, if not 
possible, ↑ to 240 mg po daily 
Darolutamide [package insert]. Whippany, NJ: Bayer; 2019
Apalutamide [package insert]. Guarbo, PR: Janssen Ortho LLC; 2019 











• Missed dose: Take as soon as you remember. Do not 
double up.
• Should also receive a gonadotropin-releasing hormone 
(GnRH) analog concurrently or should have had a 
bilateral orchiectomy
• Darolutamide: 
• Take with food
• Twice daily
• ≥Grade 3 toxicity or an intolerable: Hold or ↓ to 
300 mg po twice daily until symptoms improve 
may restart at 600 mg po twice daily
• Apalutamide and enzalutamide:
• Seizure: Permanently discontinue
• Ischemic cardiovascular events: Optimize
management of cardiovascular risk factors 
• Fractures: Refer to guidelines for use of bone-
targeted agents
• Enzalutamide 
• PRES: Seizure, headache, lethargy, confusion, 
blindness, and other visual and neurological 















• Ischemic heart 
disease
Darolutamide [package insert]. Whippany, NJ: Bayer; 2019
Apalutamide [package insert]. Guarbo, PR: Janssen Ortho LLC; 2019 
Enzalutamide [package insert]. Northbrook, IL: Astellas; 2019 
39
Oral Oncolytic Challenges
 There is a need to properly manage and monitor patients 
who are self-administering their treatments at home
 Presents challenges to health care providers and patients
 Common misconceptions and safety issues regarding 
oral oncolytics
 Financial toxicity
 Maximizing the efficacy of oral oncolytics
 Oncology pharmacists are uniquely positioned to mitigate 
these challenges
Weingart SN et al. 2008;6 Suppl 3:S1-14.
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Handling
 Easily administered, however, have exposure risks, similar 
to intravenous formulations
 General misconception: Exposure risk is low and therefore 
oral oncolytics present little risk and are safer to handle 
 Accidental exposure to oral oncolytics can occur at various 





 Guidelines around safe handling are still evolving
Goodin S et al. J Oncol Pract. 2011;7(1):7–12. doi:10.1200/jop.2010.000068
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Handling Recommendations for 
Health Care Providers
 Storage:
 Store in a designated area separate from noncytotoxic
agents
 Handling:
 Use personal protective clothing and equipment to 
minimize exposure and health risks
 Separate equipment should be used for cytotoxic and 
noncytotoxic agents
 Manipulations should be performed in a biological safety 
cabinet 
 Should not be dispensed using automatic counting 
machines
Goodin S et al. J Oncol Pract. 2011;7(1):7–12. doi:10.1200/jop.2010.000068
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Handling Recommendations for 
Health Care Providers
 Disposal and Cleaning of Contaminated Materials:
 All disposable protective clothing and disposable: 
Cytotoxic waste 
 All nondisposable materials: Wash or decontaminate 
thoroughly after use
 Training and Competencies for Safe Handling: 
 Orientation programs and routine training courses with 
competencies on managing exposures and handling
 A primary educator within a health care institution 
should be established as a source of referral and 
continued education on oral oncolytics
Goodin S et al. J Oncol Pract. 2011;7(1):7–12. doi:10.1200/jop.2010.000068
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Handling Recommendations for 
Patients and their Caregivers
Do’s
 Store according to package 
insert
 Keep in original container
 Use gloves and wash hands 
thoroughly before and after 
glove application
 Pour the oral chemotherapy 
agent into a bowl, or the lid of 
the pill bottle, and then pour 
the pills into the patient’s 
hand or mouth
 Soiled items should be kept 
and washed separately from 
other laundry
Don’ts
 Leave medication in open 
areas, near sources of water, 
direct sunlight
 Store medications in the 
areas where food or drinks 
are stored or consumed
 Crush, break, or chew tablets
 Discard medication down the 
toilet or in the garbage
Goodin S et al. J Oncol Pract. 2011;7(1):7–12. doi:10.1200/jop.2010.000068
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Financial Toxicity
 The advent of new options have improved patient outcomes 
 Accompanied with an increase in the monetary burden 
of cancer treatment
 Cancer has become the second most expensive disease in 
the United States
 Annual estimated cost estimated to increase from 124 
billion dollars in 2010 to 157 billion dollars in 2020
 Drug prices are a function of several factors 
 The cost of research and development
 Manufacturing costs
 Market pressures
Tran G, Zafar SY. Ann Transl Med. 2018;6(9):166. doi:10.21037/atm.2018.03.28
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Financial Toxicity
 Public and private payers have implemented cost sharing 
measures that shift more of the financial burden to patients




 Out-of-pocket (OOP) expenses
 Patients with cancer have OOP expenses that are estimated 
to be 976 to 1,170 dollars higher than patients without 
cancer
Tran G, Zafar SY. Ann Transl Med. 2018;6(9):166. doi:10.21037/atm.2018.03.28
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Financial Toxicity
 Financial toxicity: Negative impact of a cancer diagnosis on 
a patient's financial well-being resulting from direct or 
indirect costs
 Objective financial burden 
• OOP expenses
• Indirect costs
 Subjective financial distress
• Material conditions that arise from increased direct 
and indirect costs
• The psychological response as a result of efforts 
necessary to cope with the increased costs
• The coping behavior itself that patients adopt to 
manage their medical care while experiencing 
increased expenses
Tran G, Zafar SY. Ann Transl Med. 2018;6(9):166. doi:10.21037/atm.2018.03.28
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Financial Toxicity
 Yabroff et al: 20.4% of adult cancer survivors reported 
experiencing financial difficulties 
 Being unable to pay for their cancer-related medical bills
 Having to borrow money
 Going into debt
 Filing for bankruptcy
 To cope with financial toxicity, patients often resort to 
medication nonadherence
Tran G, Zafar SY. Ann Transl Med. 2018;6(9):166. doi:10.21037/atm.2018.03.28
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Adherence
 Variability in 
adherence: 50-
100%
 Both over- and 
under-adherence 





 Delays and 
changes in 
treatment
 Higher health 
utilization and 









Weingart SN et al. 2008;6 Suppl 3:S1-14.
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Barriers to Adherence: Financial 
and Access 
 Access barriers can be related to financial barriers
 Examples: 
 Prior authorizations
 High formulary tier
 Quantity limits or not covered at all
 Delays in receiving prescription
 Solutions:
 Dedicated medication assistance team
 External financial assistance programs
Weingart SN et al. 2008;6 Suppl 3:S1-14.
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Barriers to Adherence: Financial 
and Access 
 Resources
 Manufacturer’s Patient Assistance Program
 ACC Patient Assistance & Reimbursement Guide: 
https://www.accc-cancer.org/home/learn/publications/patient-
assistance-and-reimbursement-guide




 Cancer Family Relief Fund: www.cancerfamilyrelieffund.org
 Cancer Finances: www.cancerfinances.org
 Cancer Financial Assistance Coalition: www.cancerfac.org
 Leukemia & Lymphoma Society: www.lls.org/support/financial-
support
 Medicine Assistance Tool: www.medicineassistancetool.org
 NeedyMeds: www.needymeds.org  
51
Barriers to Adherence: 
Knowledge Gaps 
 Health literacy
 May lack knowledge about
 Administration schedules
 Adverse effect management
 Patient education program
 Include family members or caregivers when possible
 Patient-centered
 Teach-back method
 Provide information in multiple formats
 Multiple times
Weingart SN et al. 2008;6 Suppl 3:S1-14.
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Barriers to Adherence: 
Knowledge Gaps 
Tips & Tools. LONSURF® (trifluridine and tipiracil) tablets. https://www.lonsurf.com/patient-resources/tools.
53
Barriers to Adherence: 
Cognitive and Knowledge Gaps 
 Solutions continued: 
 Multinational Association for Supportive Care in Cancer 
(MASCC) Oral Agent Teaching Tool (MOATT): 
https://www.mascc.org/assets/Guidelines-
Tools/moatt_v1.2.pdf
 Dana-Farber oral chemotherapy fact sheet: 
https://www.dana-farber.org/health-
library/articles/oral-chemotherapy-fact-sheet/









Barriers to Adherence: Adverse 
Effects
 Misconception: Adverse effects from oral oncolytics will be 
less severe than side effects from intravenous therapy
 May adjust their adherence to minimize adverse effects
 Solutions:
 Ensure patients, families, and caregivers understand 
• Possible adverse effects
• How to manage adverse effects
• When and whom to call before stopping or altering 
drug administration
• Address fears regarding reporting adverse effects 
 Managing side effects: 
http://chemocare.com/chemotherapy/side-
effects/default.aspx
Weingart SN et al. 2008;6 Suppl 3:S1-14.
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Barriers to Adherence: Adverse 
Effects
Managing Side Effects. Chemocare. http://chemocare.com/chemotherapy/side-effects/default.aspx. 
59
Summary
 First oral oncolytics approved in 1953
 Mercaptopurine, methotrexate
 Proper precautions should still be taken when handling
 Adverse effects are still possible
 Increase in oral oncolytics
 2019: 7 agents approved in 1 year
 Advantages: Decreased trips to physician’s office or clinic
 Disadvantages: Financial toxicity, minimal monitoring and 
maximizing efficacy largely dependent upon patient
 Solutions: Patient assistance programs/external programs, 
education/counseling, calendars and other tools for 
maximizing adherence
Weingart SN et al. 2008;6 Suppl 3:S1-14.
Tran G, Zafar SY. Ann Transl Med. 2018;6(9):166. doi:10.21037/atm.2018.03.28
Goodin S et al. J Oncol Pract. 2011;7(1):7–12. doi:10.1200/jop.2010.000068
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